The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

Molecular Pharmacology

Volumn 67, Issue 4, 2005, Pages 1268-1282

  Watson, Christian ^a   Jenkinson, Stephen ^a   Kazmierski, Wieslaw ^a   Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 [[4 [[1 BUTYL 3 [CYCLOHEXYL(HYDROXY)METHYL] 2,5 DIOXO 1,4,9 TRIAZASPIRO[5.5]UNDEC 9 YL]METHYL]PHENYL]OXY]BENZOIC ACID; 4,6 DIMETHYL 5 [[4 METHYL 4 [3 METHYL 4 [2 (METHOXY) 1 [4 (TRIFLUOROMETHYL)PHENYL]ETHYL] 1 PIPERAZINYL] 1 PIPERIDINYL]CARBONYL]PYRIMIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CALCIUM; CHEMOKINE RECEPTOR CCR5; COMPOUND 873140; IODINE 125; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RANTES; UNCLASSIFIED DRUG; VICRIVIROC;

ALLOSTERISM; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANCE; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTOPE LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTI-HIV AGENTS; BENZOATES; CHO CELLS; CRICETINAE; CYCLIC N-OXIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; MACROPHAGE INFLAMMATORY PROTEIN-1; PIPERAZINES; PIPERIDINES; PYRIDINES; RANTES; RECEPTORS, CCR5; SPIRO COMPOUNDS;

EID: 15744391870     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.008565     Document Type: Article

References (54)

1. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, and Berger EA (1996) CC CKR5: A RANTES, MIP-1, MIP-1 receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (Wash DC) 272:1955-1958.
2. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, and Goldsmith M (1996) Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science (Wash DC) 274:1924-1926.
3. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawad H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, et al. (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96:5698-5703.
4. Baroudy B, Clader JW, Josien HB, McCombie SW, McKittrick BA, Miller MW, Neustadt BR, Palani A, Steensma R, Tagat JR, et al. (2000a) PCT Int. Appl. WO 2000066559.
5. Baroudy BM, Clader JW, Josien HB, Mccombie SW, Mckittrick BA, Miller MW, Neustadt BR, Palani A, Smith EM, Steensma R, et al. (2000b) PCT Int. Appl., WO 2000066558.
6. Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, and Cullen BR (1997) Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. EMBO (Eur Mol Biol Organ) J 16:2599-2609.
7. Blanpain C, Vanderwinden J-M, Cihak J, Wittamer V, Le Poul E, Issafras H, Strangassinger M, Vassart G, Marullo S, Schlondorff D, et al. (2002) Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell 13:723-737.
8. Blanpain C, Doranz BJ, Bondue A, Govaerts C, De Leener A, Vassart G, Doms RW, Proudfoot A, and Parmetier M (2003) The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem 278:5179-5187.
9. Cheng YC and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, MacKay CR, LaRosa G, Newman G, et al. (1996) The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
11. Christopolous A and Kenakin TP (2002) G-protein coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
12. Conklin BR, Farfel Z, Lustig KD, Julius D, and Bourne HR (1993) Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature (Lond) 363:274-276.
13. Cox MA, Jenh C-H, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, and Hipkin RW (2001) Human interferon-inducible 10-kDa protein and human interferon-inducible T cell a chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 59:707-715.
14. th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California.
15. Demarest J, Shibayama S, Ferris R, Vavro C, St. Clair M, and Boone L (2004) A novel CCR5 antagonist, 873140, exhibits potent in vitro anti-HIV activity. Abstract WeOrA1231. The XV International AIDS Conference; 2004 Jul 11-16; Bangkok, Thailand.
16. Deng H, Unutmaz D, Kewalramani VN, and Littman DR (1997) Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature (Lond) 388:296-300.
17. Doms RW and Peiper SC (1997) Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virol 235:179-190.
18. Doranz BJ, Lu Z-H, Rucker J, Zhang T-Y, Sharron M, Cen Y-H, Wang Z-X, Guo H-H, Du J-D, Accavitti MA, et al. (1997) Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1 J Virol 71:6305-6314.
19. Doranz BJ, Rucker J, Smyth Y, Samson RJ, Peiper SC, Parmentier M, Collman RG, and Doms RW (1996) A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell 85: 1149-1158.
20. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar SP, et al. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 97:5639-5644.
21. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
22. Fillion G, Rousselle JC, Massot O, Zifa E, Fillion MP, and Prudhomme N (1996) A new peptide, 5-HT moduline, isolated and purified mammalian brain specifically interacts with 5-HT1B/1D receptors. Behav Brain Res 73:313-317.
23. Finke PE, Oates B, Mills SG, MacCross M, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Carella A, Carver G, et al. (2001) Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N- (alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg Med Chem Lett 11: 2475-2479.
24. Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423.
25. Kazmierski WM, Bifulco N, Yang H, Boone L, DeAnda F, Watson C, and Kenakin T (2003) Recent progress in discovery of small-molecule CCR5 Chemokine receptor ligands as HIV-1 inhibitors. Bioorg Med Chem 11:2663-2676.
26. Kazmierski WM, Boone L, Lawrence W, Watson C, and Kenakin T. CCR5 chemokine receptors: gatekeepers of HIV-1 infection (2002) Curr Drug Targets Infect Disord 2:265-278.
27. Kenakin TP (2004a) A Pharmacology Primer: Theory, Application and Methods. Academic Press, San Diego, CA.
28. Kenakin TP (2004b) Allosteric modulators; the new generation of receptor antagonist. Mol Interv 4:222-229.
29. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, et al. (2004) Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape form small-molecule CCR inhibitor. J Virol 78:2790-2807.
30. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendricks WA (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody Nature (Lond) 393:648-659.
31. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell R, et al. (1999) Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 274:9617-9626.
32. Litschig S, Gasparini F, Rueegg DF, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, and Kuhn R (1999) CPCCOEt, a noncompetitive metabotropic glutamate 1 receptor antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55:453-461.
33. Luckow VA, Lee SC, Barry GF, and Olis PO (1993) Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. J Virol 67:4566-4579.
34. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Sbibayama S, Sagawa K, Fukushima D, Moravek J, et al. (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78:8654-8662.
35. 1B/1D receptors. Mol Pharmacol 50:752-762.
36. O'Reilly DR, Miller LK, and Luckow VA (1992) Baculovirus Expression Vectors: a Laboratory Manual. Oxford University Press, New York.
37. Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, Endres M, and Baroudy BH (2001) Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl]- 1′-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4′-methyl-1,4′- bipiperidine-N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J Med Chem 44:3339-3342.
38. Perros M, Price DA, Stammen BL, Wood A. PCT Int. Appl. (2001), WO 2001090106.
39. Picard L, Simmons G, Power CA, Meyer A, Wiess RA, and Clapham PR (1997) Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion J Virol 71:5003-5011.
40. Poignard P, Saphire EO, Parren PW, and Burton DR (2001) gp120: biologic aspects of structural features. Annu Rev Immunol 19:253-274.
41. Rizzuto CD, Wyatt R, Hernández-Ramos N, Sun Y, Kwong PD, Hendrickson WA and Sodroski J (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (Wash DC) 280:1949-1953.
42. Ross T, Bieniasz PD, and Cullen BR (1999) Role of chemokine receptors in HIV-1 infection and pathogenesis Adv Virus Res 52:233-267.
43. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JFY, Collman RG, Doranz BJ, Doms RW, and Parmentier M (1997) Utilization of chemokine receptors, orphan receptors and herpesvirus- encoded receptors by diverse human and simian immunodeficiency viruses J Virol 71:8999-9007.
44. Sabroe I, Peck MJ, Van Keulen BJ, Jorritsma A, Simmons G, Clapham PR, Williams TJ, and Pease JE (2000) A small molecule antagonist of chemokine receptors CCR1 and CCR3. J Biol Chem 275:25985-25992.
45. Shieh JTC, Albright AV, Sharron M, Gartner S, Stritzki J, Doms RW, and Gonzalez-Scarano F (1998) Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia. J Virol 72:4243-4249.
46. Smyth RJ, Yi Y, Singh A, and Collman RG (1998) Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J Virol 72:4478-4484.
47. Staudinger R, Wang X, and Bandres JC (2001) Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope. Biochem Biophys Res Commun 286:41-47.
48. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Anandan P, Shapiro S, Clader JW, et al. (2001) SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 98:12718-12723.
49. Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, Strizki JM, Baroudy BM, Cox K, Lachowicz J, et al. (2004) Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5- pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl) phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective and orally bioavailable CCR5 antagonist. J Med Chem 47: 2405-2408.
50. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, et al. (2002) HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 99:395-400.
51. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, et al. (2003) Analysis of the mechanism by which the small molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type-1 entry. J Virol 77:5201-5208.
52. Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, Chen J, Humblias J, Samson M, Parmentier M, et al. (1997) Interaction of the chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 186:1373-1381.
53. Wyatt R and Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science (Wash DC) 280:1884-1888.
54. Zhang Y-J and Moore JP (1999) Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J Virol 73:3443-3448.